Świerkot Jerzy, Lewandowicz-Uszyńska Aleksandra, Bogunia-Kubik Katarzyna
Klinika Reumatologii i Chorób Wewnętrznych, Uniwersytet Medyczny we Wrocławiu.
III Katedra Pediatrii, Klinika Immunologii i Reumatologii Wieku Rozwojowego, Uniwersytet Medyczny we Wrocławiu; Oddział Immunologii Klinicznej i Pediatrii, WSS. im. J.Gromkowskiego we Wrocławiu.
Postepy Hig Med Dosw (Online). 2013 Dec 11;67:1254-60. doi: 10.5604/17322693.1079819.
Patients with systemic inflammatory rheumatic diseases (such as rheumatoid arthritis, lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathies, or Sjögren's syndrome) are at increased risk of cancer, including hematological malignancies (leukemias and lymphomas), as well as non-hematological cancers (e.g. lung, esophageal, prostate or ovarian cancer). This increased risk for cancer development in patients with rheumatic diseases is attributed to the immune (autoimmune) processes and the medical treatment. Due to the often similar symptoms and the occurrence of systemic paraneoplastic syndromes it is very important to evaluate the association between rheumatic diseases and cancer. This paper presents issues concerning the development of cancer in patients with rheumatic diseases and the risk of cancer associated with drugs used for the treatment of rheumatic diseases.
患有全身性炎症性风湿性疾病(如类风湿性关节炎、红斑狼疮、系统性硬化症、特发性炎症性肌病或干燥综合征)的患者患癌症的风险增加,包括血液系统恶性肿瘤(白血病和淋巴瘤)以及非血液系统癌症(如肺癌、食管癌、前列腺癌或卵巢癌)。风湿性疾病患者癌症发生风险增加归因于免疫(自身免疫)过程和药物治疗。由于症状常常相似且会出现全身性副肿瘤综合征,评估风湿性疾病与癌症之间的关联非常重要。本文阐述了有关风湿性疾病患者癌症发生以及与用于治疗风湿性疾病的药物相关的癌症风险问题。